Latest News and Press Releases
Want to stay updated on the latest news?
-
Data from the ASCENT study of LIQ861 (YUTREPIA™) in PH-ILD patients highlights safety, tolerability, exploratory changes in 6MWD, cardiac effort and QoL.
-
LIQ861 was well-tolerated in PAH patients at two-weeks of treatment, the safety endpoint requested by U.S. FDANDA submission targeted for late 2019 RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2019 ...
-
Completed enrollment of the safety portion of our Ph3 LIQ861 (INSPIRE) clinical trialTwo-week safety Ph3 LIQ861 data readout anticipated in the first quarter of 2019Dr. Stephen Bloch appointed as...